The Valvara Tissue Intelligence System (TIS) brings clinical-grade bioimpedance and tissue dielectric measurement to the point of care — objective tissue health intelligence in a single handheld scan.
Clinicians managing lymphedema, post-surgical recovery, and chronic edema still rely on tape measures and subjective assessment — tools that miss subclinical changes until the window for early intervention has closed.
Valvara changes that. The Tissue Intelligence System (TIS) combines bioimpedance spectroscopy (BIS) and tissue dielectric constant (TDC) measurement into a single handheld scan, delivering our proprietary Depth-Gradient Fluid Index — quantitative tissue health data that enables earlier detection, smarter intervention, and measurable outcomes.
Combined BIS + TDC in a single handheld device — multi-frequency bioimpedance validated against gold-standard methods.
Our proprietary DGFI algorithm characterizes tissue fluid across depth layers — insight no single modality can provide alone.
Designed for the therapist's hands and the clinician's workflow — bringing objective tissue measurement to every visit, every patient.
Multi-modal sensing differentiates fluid compartments, tissue composition, and early pathological change.
Multi-frequency impedance measurement across a broad spectrum enables precise differentiation of extracellular and intracellular fluid compartments — the clinical gold standard for lymphedema quantification.
Core MeasurementLocalized tissue water content measurement at controlled depths complements BIS with spatial resolution — together providing a complete picture of tissue fluid dynamics no single modality achieves alone.
Depth ProfilingValvara's proprietary DGFI algorithm fuses BIS and TDC data into a single composite index that characterizes tissue health across depth gradients — our core IP and clinical differentiator.
Proprietary AlgorithmA portable, clinician-owned wand that goes where the therapist goes — hospital, outpatient clinic, home visit, or satellite office. No floor-standing hardware. No hospital IT integration required.
Point of CareLongitudinal trend visualization, anomaly flagging, and structured clinical reports give care teams actionable tissue health intelligence without adding workflow burden.
Software / SaaSIntegrated thermistors, pressure sensors, and contextual data enhance diagnostic accuracy and enable activity-adjusted, anatomically-aware tissue characterization.
Sensor ArchitectureThe clinicians treating lymphedema, post-surgical recovery, and chronic edema are working with tools built for a different era — or no objective tools at all. Valvara is building what tissue measurement should have been all along.
Valvara begins with lymphedema — the clearest clinical need and the most established bioimpedance evidence base. The platform is designed from day one to expand across conditions where tissue fluid dynamics and composition are clinically meaningful.
Primary indication · Early detection & staging
Adipose tissue differentiation · Disease monitoring
Recovery monitoring · Complication detection
Fluid overload monitoring · Decompensation prediction
Muscle mass tracking · Aging populations
Post-oncology lymphedema · Radiation sequelae
Maternal fluid surveillance · Risk stratification
Expanding pipeline across oncology, nephrology & beyond
Platform expansion strategy covers 26+ clinical applications across 5 anatomical zones
Valvara is co-founded by a clinical expert who has treated lymphedema patients firsthand and a technical founder building the IP, engineering, and business infrastructure to bring this to market.
OTR/L, CLT-LANA. Certified lymphedema therapist with direct clinical experience treating the patients Valvara is built for. Drives clinical validation, customer discovery, and the go-to-market strategy rooted in real practitioner workflows.
Leads IP strategy, engineering partnerships, and business development. Architect of Valvara's patent portfolio spanning hardware, algorithms, clinical applications, and business methods.
A pre-seed SAFE round is underway. We're selective about partners — looking for investors with conviction in medical devices, point-of-care diagnostics, and clinician-led companies. Reach out for terms, diligence materials, and a conversation.
We review every inquiry personally. Submit below and we'll respond by email within 2 business days.
Prefer email? Reach us directly at investors@valvara.com